Results 151 to 160 of about 22,983,555 (247)
Artificial Intelligence for Integrated Analysis of Non-Blood Biological Fluids: From Biomarker Discovery to Clinical Decision-Support Systems. [PDF]
Becherucci V, Romano F, Russo E.
europepmc +1 more source
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens +6 more
wiley +1 more source
Patient misidentification and data integrity risks in ultrasound imaging: a case report using multi-framework incident analysis. [PDF]
Osei-Donkor B, Hassoun A, Jabin MSR.
europepmc +1 more source
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober +16 more
wiley +1 more source
Ultratrace Osmium in Wild Mushrooms: Environmental Occurrence and Chemical-Form-Dependent Molecular and Toxicological Interpretation. [PDF]
Peña-Fernández A +2 more
europepmc +1 more source
MITF maintains genome stability in nonmelanocyte lineages
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir +13 more
wiley +1 more source
Key considerations when assessing clinical utility for biomarker testing: A checklist. [PDF]
Wang T +4 more
europepmc +1 more source
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
Task-Specific Multimodal Imaging and Spectroscopy for Post-Mortem Interval Assessment in Human Skeletal Remains: An Exploratory Decision-Support Framework. [PDF]
Pallua JD +7 more
europepmc +1 more source

